Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

Next Previous
Trial Profile

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Calaspargase pegol (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Dexrazoxane (Primary) ; Doxorubicin (Primary) ; Folinic acid (Primary) ; Folinic acid (Primary) ; Hydrocortisone (Primary) ; Methotrexate (Primary) ; Venetoclax (Primary) ; Vincristine (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 17 Feb 2025 Planned End Date changed from 2 Apr 2027 to 2 Jul 2028.
  • 17 Feb 2025 Planned primary completion date changed from 2 Apr 2025 to 2 Jul 2026.
  • 09 Mar 2023 Planned initiation date (estimated date of first participant enrollment) changed from 1 Feb 2023 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top